OVCAS1
MCID: OVR114
MIFTS: 38

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 56 29
Ovarian Cancer, Susceptibility to, 1 56 13
Ovarian Cancer, Susceptibility to 56
Malignant Neoplasm of Ovary 71
Epithelial Ovarian Cancer 71
Ovarian Carcinoma 71
Ovarian Cancer 56
Ovcas1 56

Classifications:



External Ids:

OMIM 56 607893
UMLS 71 C0029925 C0677886 C1140680

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian cancer, susceptibility to, 1, is related to ovarian cancer and hereditary breast ovarian cancer syndrome, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is OVCAS1 (Ovarian Cancer, Epithelial, Susceptibility To). The drugs Diclofenac and Aprepitant have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and lung.

More information from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 925)
# Related Disease Score Top Affiliating Genes
1 ovarian cancer 27.4 PHF13 OVCAS1 FILIP1L DPH1
2 hereditary breast ovarian cancer syndrome 12.8
3 breast-ovarian cancer, familial 2 12.7
4 breast-ovarian cancer, familial 3 12.6
5 breast-ovarian cancer, familial 4 12.6
6 familial ovarian cancer 12.3
7 hereditary site-specific ovarian cancer syndrome 12.2
8 ovarian epithelial cancer 12.1
9 fallopian tube carcinoma 11.7
10 pancreatic cancer 11.6
11 paraneoplastic cerebellar degeneration 11.6
12 ovarian small cell carcinoma 11.6
13 ovarian germ cell cancer 11.6
14 breast cancer 11.5
15 lynch syndrome 11.5
16 ovarian disease 11.5
17 ovarian melanoma 11.4
18 malignant ovarian cyst 11.4
19 ovarian lymphoma 11.4
20 malignant teratoma 11.4
21 breast-ovarian cancer, familial 1 11.3
22 enchondromatosis, multiple, ollier type 11.1
23 sex cord-gonadal stromal tumor 11.1
24 atypical teratoid rhabdoid tumor 11.1
25 ovarian malignant mesothelioma 11.1
26 ovary sarcoma 11.1
27 ovary epithelial cancer 11.1
28 ovary neuroendocrine neoplasm 11.1
29 ovarian clear cell malignant adenofibroma 11.1
30 granulosa cell tumor of the ovary 11.1
31 gynandroblastoma 11.1
32 neutropenia 11.0
33 endometriosis 10.9
34 serous cystadenocarcinoma 10.9
35 endometrial cancer 10.8
36 ovary adenocarcinoma 10.8
37 adenocarcinoma 10.8
38 cystadenocarcinoma 10.8
39 alopecia 10.7
40 ovarian cyst 10.7
41 neuropathy 10.7
42 peripheral nervous system disease 10.7
43 thrombocytopenia 10.7
44 malignant epithelial tumor of ovary 10.7
45 infertility 10.6
46 severe combined immunodeficiency 10.6
47 mucositis 10.6
48 primary peritoneal carcinoma 10.6
49 b-cell lymphoma 10.6
50 peritonitis 10.6

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM:

607893

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 541)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
3
Fosaprepitant Approved Phase 4 172673-20-0 219090
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
tannic acid Approved Phase 4 1401-55-4
6
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
7
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
8
Ferrous fumarate Approved Phase 4 141-01-5
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
10
Remifentanil Approved Phase 4 132875-61-7 60815
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
13
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
14
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
15
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
16
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
19
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
20 Neurotransmitter Agents Phase 4
21 neurokinin A Phase 4
22
Substance P Phase 4 33507-63-0 44359816
23 Progestins Phase 4
24 Follicle Stimulating Hormone Phase 4
25
Apatinib Phase 4 811803-05-1
26
Isophosphamide mustard Phase 4 0
27 Anesthetics Phase 4
28 Hypnotics and Sedatives Phase 4
29 Anesthetics, General Phase 4
30 Anesthetics, Intravenous Phase 4
31 Anesthetics, Inhalation Phase 4
32 Platelet Aggregation Inhibitors Phase 4
33 Antipyretics Phase 4
34
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
35
Hydralazine Approved Phase 3 86-54-4 3637
36
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
37
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
38
Epirubicin Approved Phase 3 56420-45-2 41867
39
Ethanol Approved Phase 3 64-17-5 702
40
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
41
Tranexamic Acid Approved Phase 3 1197-18-8 5526
42
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
43
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
44
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
45
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
46
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
47
Adenosine Approved, Investigational Phase 3 58-61-7 60961
48
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
49
Tamoxifen Approved Phase 3 10540-29-1 2733526
50
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 2181)
# Name Status NCT ID Phase Drugs
1 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Unknown status NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
2 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
3 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
4 Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function Unknown status NCT02103244 Phase 4 Carboplatin
5 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
6 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
7 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
8 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
9 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
10 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
11 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
12 A Phase IV, Open-label, Post Marketing, Prospective, Randomized, Controlled, Multicentre, Multinational Study to Investigate Tailoring of Recombinant FSH Use in Ovulation Stimulation Treatment in Chronic Anovulatory Subjects (WHO Group II) Completed NCT01081626 Phase 4 Recombinant FSH (follitropin alpha)
13 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
14 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
15 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
16 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
17 The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies Recruiting NCT03858166 Phase 4 PEG-rhG-CSF
18 Biomarker Guided Treatment in Gynaecological Cancer Recruiting NCT02543710 Phase 4 Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer
19 Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Recruiting NCT04223583 Phase 4 Anlotinib Hydrochloride
20 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
21 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
22 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
23 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Not yet recruiting NCT04352439 Phase 4 Aspirin
24 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
25 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
26 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
27 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
28 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
29 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
30 Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line Unknown status NCT01802749 Phase 3 Bevacizumab;Paclitaxel;Carboplatin;pegylated liposomal doxorubicin;Gemcitabine
31 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
32 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
33 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
34 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
35 Weekly Versus Every 3 Week Carboplatin and Paclitaxel in Patients With Ovarian Cancer: a Phase III Randomized Multicenter Study Unknown status NCT00660842 Phase 3 paclitaxel;carboplatin;paclitaxel
36 Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm Unknown status NCT01461850 Phase 3 Neoadjuvant chemotherapy + Interval Debulking Surgery
37 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
38 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
39 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
40 Phase 3 Study of Lobaplatin,5-Fluorouracil and Leucovorin for the Treatment of Recurrent or Metastatic Esophageal Carcinoma Unknown status NCT01034683 Phase 3 lobaplatin , 5-FU ,leucovorin
41 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
42 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
43 Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23 Unknown status NCT02903004 Phase 3 Trabectedin;Pegylated Liposomal Doxorubicin;Topotecan;Gemcitabine;Weekly Paclitaxel;Carboplatin
44 Long Term Outcomes After EUS-guided Ablation for Cystic Tumors of the Pancreas Unknown status NCT00689715 Phase 2, Phase 3
45 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Unknown status NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
46 Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial Unknown status NCT02349763 Phase 3 Intravenous Dexamethasone;Oral Dexamethasone
47 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00102414 Phase 3 Gemcitabine
48 A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00477282 Phase 3 Karenitecin;Topotecan
49 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00102375 Phase 3 Topotecan
50 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

40
Breast, Testes, Lung, T Cells, Ovary, Prostate, Colon

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 86)
# Title Authors PMID Year
1
Localization of a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. 56
11440995 2001
2
Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer. 61
32346557 2020
3
The relation of healthy and Western dietary patterns to the risk of endometrial and ovarian cancers: a systematic review and meta-analysis. 61
30806608 2020
4
Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases. 61
31301021 2020
5
Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin. 61
31277885 2019
6
Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer. 61
31610315 2019
7
Low Prevalence of the Four Common Colombian Founder Mutations in BRCA1 and BRCA2 in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer. 61
30541753 2019
8
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. 61
30229512 2019
9
Chromatin-Remodeling Factor SPOC1 Acts as a Cellular Restriction Factor against Human Cytomegalovirus by Repressing the Major Immediate Early Promoter. 61
29743358 2018
10
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 61
29454514 2018
11
Stereotactic radiosurgery for focal leptomeningeal disease in patients with brain metastases. 61
28536993 2017
12
Data on the association of CMPK1 with clinicopathological features and biological effect in human epithelial ovarian cancer. 61
28560285 2017
13
Carboplatin/taxane-induced gastrointestinal toxicity: a pharmacogenomics study on the SCOTROC1 trial. 61
26194361 2016
14
[Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer]. 61
27116987 2016
15
Expression and clinical significance of cortactin protein in ovarian neoplasms. 61
26243395 2016
16
Egg intake and cancers of the breast, ovary and prostate: a dose-response meta-analysis of prospective observational studies. 61
26293984 2015
17
Unexpected ovarian malignancy following laparoscopic excision of adnexal masses. 61
24964925 2014
18
Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. 61
24680770 2014
19
Contrast harmonic endoscopic ultrasonography in the characterization of pancreatic metastases (with video). 61
24713844 2014
20
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. 61
23756764 2014
21
High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. 61
24361578 2014
22
Management and prevention of chylous leakage after laparoscopic lymphadenectomy. 61
25268098 2014
23
Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer. 61
23921967 2013
24
A pilot study of an exercise & cognitive behavioral therapy intervention for epithelial ovarian cancer patients. 61
23557323 2013
25
SPOC1 modulates DNA repair by regulating key determinants of chromatin compaction and DNA damage response. 61
23034801 2012
26
Fibroblast growth factor receptor 3 is highly expressed in rarely dividing human type A spermatogonia. 61
22777346 2012
27
Evaluation of Society of Gynecologic Oncologists (SGO) ovarian cancer quality surgical measures. 61
22561039 2012
28
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer. 61
21380784 2012
29
[III. Ovarian cancer 1. Ovarian clear cell carcinoma]. 61
22545287 2012
30
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer. 61
22001143 2012
31
Current clinical practice in cytoreductive surgery for advanced ovarian cancer: a European survey. 61
21892096 2011
32
Laparoscopic major gynecologic surgery in patients with prior laparotomy bowel resection. 61
22643497 2011
33
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: results of an Austrian gynecologic oncologists' expert meeting. 61
21072604 2010
34
The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. 61
19552944 2009
35
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases. 61
19018599 2009
36
Psychosocial consequences of genetic counseling: a population-based follow-up study. 61
19120380 2009
37
[Relationship between hormone therapy in women with ovarian malignancy and prognosis]. 61
19087569 2008
38
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. 61
18794120 2008
39
[Adenovirus mediated angiostatin gene therapy for ovarian cancer: experiment with nude mice]. 61
19080673 2008
40
Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis. 61
17688927 2007
41
Expression of organic cation transporter SLC22A16 in human epithelial ovarian cancer: a possible role of the adriamycin importer. 61
17581421 2007
42
Centralization of care for patients with advanced-stage ovarian cancer: a cost-effectiveness analysis. 61
17354232 2007
43
Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. 61
17359531 2007
44
[186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast. 61
17043634 2006
45
[Influence of gonadotropin-releasing hormone agonist on the effects of chemotherapy upon ovarian cancer: an experimental study with rat model]. 61
16029659 2005
46
Endothelial monocyte activating polypeptide-II induced gene expression changes in endothelial cells. 61
15935955 2005
47
Gene expression in the spermatogenically inactive "dark" and maturing "light" testicular tissues of the prepubertal colt. 61
15223842 2004
48
Gonadotropin-induced gene regulation in human granulosa cells obtained from IVF patients: modulation of genes coding for growth factors and their receptors and genes involved in cancer and other diseases. 61
15067357 2004
49
[Role of positron emission tomography in diagnosis of recurrent ovarian cancer]. 61
14728852 2003
50
[An experimental research in the inhibiting effect of bFGF-MAb on the growth of ovarian cancer cells and transplanted tumor]. 61
14619564 2003

Variations for Ovarian Cancer 1

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

GO Terms for Ovarian Cancer 1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....